What we do Shree Ganesh Remedies Ltd manufactures pharmaceutical intermediates and specialty fine chemicals for domestic and export markets, with expertise in complex chemical synthesis. |
Founded in 1,995 |
Market share A key player in pharmaceutical intermediates with growing global foothold in 20+ countries, expanding specialty chemicals business. |
Problem solved Provides complex, high-quality pharmaceutical intermediates and specialty chemicals, supporting global pharma and fine chemical industries' demand. |
Top clients or who we serve Serves global pharmaceutical companies across EU, US, and India; caters primarily to B2B markets with custom synthesis solutions. |
Key management Chandu Kothia (Managing Director), Gunjan Kothia (Head of Business Development & Innovation), Parth Kothia (Whole Time Director & CFO). |
Our journey and innovations Founded in 1995, became public in 2017; expanded multiple plants, acquired Ashok Pharma Chem, and commissioned advanced facilities including a high-pressure reaction block. |
Where we operate Manufacturing and sales primarily in India and international markets including Europe, United States, and over 20 countries globally. |
Top products or what we offer Pharmaceutical intermediates related to antipsychotic, antiseptic, antiviral, and specialty fine chemicals with advanced synthesis technologies. |
Top brands Not applicable (focus on custom intermediates and fine chemicals rather than consumer brands). |
Raw materials needed Chemical reagents including halogenating agents, catalytic metals, hydride salts, and specialty chemicals. |
Raw materials supplier Not specified; sources likely global and domestic chemical suppliers. |
Recurring vs cyclical contribution Revenue mainly from custom synthesis contracts and intermediates; moderately recurring with some project-based cyclical elements. |
Our industry position Emerging leader in complex pharmaceutical intermediates; strong growth in specialty chemicals and CRAMS segments. |
Financial highlights FY25 revenue ₹108.6 Cr, PAT ₹23.1 Cr; consistent profitable growth with 5-year CAGR ~22% revenue, 24% PAT. |
Geographical revenue split 67% revenue from outside India; 41% from domestic operations. |
Order book - |
Whats driving growth Strategic R&D, expanded manufacturing capacity including new pilot plants and blocks, and increasing CRAMS engagements. |
Our future plans Commission Plant 7 by H1FY27, expand R&D and pilot facilities, develop larger scale projects at newly acquired Dahej site. |
Our green promise ISO 14001 certified with renewable energy adoption, waste recycling, advanced effluent treatments, and emission controls. |
Our people and values Employee safety prioritized via comprehensive health and safety protocols; culture encourages innovation and ethical practices. |
Key challenges ahead Near-term revenue pressures from global demand softness, competitive pricing, and shipment delays. |
Interesting facts Operates one of India’s few advanced high-pressure reaction blocks and maintains a portfolio involving multiple complex chemistries. |
Risks and strategy Mitigates risks via diversification into specialty chemicals, scale expansion, and strong customer partnerships. |
